These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 17195231

  • 1. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus.
    Aringer M, Steiner G, Graninger WB, Höfler E, Steiner CW, Smolen JS.
    Arthritis Rheum; 2007 Jan; 56(1):274-9. PubMed ID: 17195231
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
    Aringer M, Graninger WB, Steiner G, Smolen JS.
    Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222
    [Abstract] [Full Text] [Related]

  • 3. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
    Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN.
    Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
    [Abstract] [Full Text] [Related]

  • 4. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, Steiner G, Smolen JS.
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [Abstract] [Full Text] [Related]

  • 5. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [Abstract] [Full Text] [Related]

  • 6. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
    De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2003 Apr; 48(4):1015-23. PubMed ID: 12687543
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of infliximab in active SLE: a pilot study.
    Uppal SS, Hayat SJ, Raghupathy R.
    Lupus; 2009 Jul; 18(8):690-7. PubMed ID: 19502264
    [Abstract] [Full Text] [Related]

  • 8. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
    Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S.
    Ann Rheum Dis; 2005 Mar; 64(3):403-7. PubMed ID: 15297281
    [Abstract] [Full Text] [Related]

  • 9. Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features.
    Jimenez-Boj E, Kedersha N, Tohidast-Akrad M, Karlhofer FM, Stummvoll G, Zimmermann C, Ulrich W, Guiducci S, Hoefler E, Aringer M, Schett G, Matucci-Cerinic M, Smolen JS, Steiner G.
    Arthritis Rheum; 2008 May; 58(5):1226-36. PubMed ID: 18438838
    [Abstract] [Full Text] [Related]

  • 10. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
    Ebert EC, Das KM, Mehta V, Rezac C.
    Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498
    [Abstract] [Full Text] [Related]

  • 11. BioPlex 2200 multiplexed system: simultaneous detection of anti-dsDNA and anti-chromatin antibodies in patients with systemic lupus erythematosus.
    Bardin N, Desplat-Jego S, Daniel L, Jourde Chiche N, Sanmarco M.
    Autoimmunity; 2009 Jan; 42(1):63-8. PubMed ID: 19127456
    [Abstract] [Full Text] [Related]

  • 12. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
    Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ.
    J Rheumatol; 2006 Jan; 33(1):24-30. PubMed ID: 16395746
    [Abstract] [Full Text] [Related]

  • 13. Induction of endothelial cell apoptosis by heat-shock protein 60-reactive antibodies from anti-endothelial cell autoantibody-positive systemic lupus erythematosus patients.
    Dieudé M, Senécal JL, Raymond Y.
    Arthritis Rheum; 2004 Oct; 50(10):3221-31. PubMed ID: 15476243
    [Abstract] [Full Text] [Related]

  • 14. Therapeutic blockade of TNF in patients with SLE-promising or crazy?
    Aringer M, Smolen JS.
    Autoimmun Rev; 2012 Mar; 11(5):321-5. PubMed ID: 21619949
    [Abstract] [Full Text] [Related]

  • 15. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus.
    Tew GW, Rabbee N, Wolslegel K, Hsieh HJ, Monroe JG, Behrens TW, Brunetta PG, Keir ME.
    Lupus; 2010 Feb; 19(2):146-57. PubMed ID: 19946034
    [Abstract] [Full Text] [Related]

  • 16. [Determination of anti dsDNA antibodies by immunofluorescence using Crithidia luciliae. I--Diagnostic and prognostic value in systemic lupus erythematosus. Comparison with the Farr radioimmunoassay].
    Borda-Iriarte O, Meyer O, Cyna J, Haïm T, Ryckewaert A.
    Rev Rhum Mal Osteoartic; 1984 Apr; 51(4):185-91. PubMed ID: 6374861
    [Abstract] [Full Text] [Related]

  • 17. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
    Morimoto S, Nakano S, Watanabe T, Tamayama Y, Mitsuo A, Nakiri Y, Suzuki J, Nozawa K, Amano H, Tokano Y, Kobata T, Takasaki Y.
    Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
    [Abstract] [Full Text] [Related]

  • 18. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus.
    Husebye ES, Sthoeger ZM, Dayan M, Zinger H, Elbirt D, Levite M, Mozes E.
    Ann Rheum Dis; 2005 Aug; 64(8):1210-3. PubMed ID: 15708887
    [Abstract] [Full Text] [Related]

  • 19. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
    Poulalhon N, Begon E, Lebbé C, Lioté F, Lahfa M, Bengoufa D, Morel P, Dubertret L, Bachelez H.
    Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
    [Abstract] [Full Text] [Related]

  • 20. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis.
    Krüger-Krasagakis S, Galanopoulos VK, Giannikaki L, Stefanidou M, Tosca AD.
    Br J Dermatol; 2006 Mar; 154(3):460-6. PubMed ID: 16445776
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.